Nektar Therapeutics | NKTR - Net Income


Nektar Therapeutics reported $-36.08M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
ALKERMES USD -66.48M 115.82M Mar/2026
Alterity Therapeutics Limited AUD -6.3M 525.41K Dec/2025
Amgen USD 1.82B 486M Mar/2026
Baxter International USD -15M 1.11B Mar/2026
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Biogen USD 319.5M 368.4M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Cara Therapeutics USD -5.53M 621K Sep/2025
Cipla INR 5.55B 1.21B Mar/2026
Dr.Reddys Laboratories INR 2.21B 9.89B Mar/2026
Eisai JPY -3.25B 20.43B Mar/2026
Eli Lilly USD 7.4B 760M Mar/2026
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Exelixis USD 210.47M 34.06M Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Grifols EUR 114.37M 34.03M Dec/2025
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Incyte USD 303.33M 4.05M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
MacroGenics USD -14.16M 30.98M Dec/2025
Merck USD -4.24B 7.2B Mar/2026
Nektar Therapeutics USD -36.08M 978K Dec/2025
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Takeda JPY -24.32B 127.96B Mar/2026
Teva Pharmaceutical Industries USD 369M 111M Mar/2026
Xencor USD -128.92M 122.26M Mar/2026